Want to see GB:GSK full AI Analyst Report?
Total Valuation
GlaxoSmithKline has a market cap or net worth of £72.72B. The enterprise value is 94.96B .
Market Cap£72.72B
Enterprise Value94.96B
Share Statistics
GlaxoSmithKline has 4,045,430,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,045,430,700
Owned by Insiders1.14%
Owned by Institutions<0.01%
Financial Efficiency
GlaxoSmithKline’s return on equity (ROE) is 0.35 and return on invested capital (ROIC) is 14.25%.
Return on Equity (ROE)0.35
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)14.25%
Return on Capital Employed (ROCE)0.18
Revenue Per Employee488.73K
Profits Per Employee85.52K
Employee Count66,841
Asset Turnover0.53
Inventory Turnover1.51
Valuation Ratios
The current PE Ratio of GlaxoSmithKline is 16.8. GlaxoSmithKline’s PEG ratio is 0.10.
PE Ratio16.8
PS Ratio2.26
PB Ratio4.51
Price to FCF12.41
Price to Operating Cash Flow8.50
PEG Ratio0.10
Income Statement
In the last 12 months, GlaxoSmithKline had revenue of 32.67B and earned 5.72B in profits. Earnings per share was 1.41.
Revenue32.67B
Gross Profit23.70B
Operating Income7.17B
Pretax Income7.40B
Net Income5.72B
EBITDA11.88B
Earnings Per Share (EPS)1.41
Cash Flow
In the last 12 months, operating cash flow was 8.56B and capital expenditures -1.72B, giving a free cash flow of 6.84B billion.
Operating Cash Flow8.56B
Free Cash Flow6.84B
Free Cash Flow per Share1.69
Dividends & Yields
GlaxoSmithKline pays an annual dividend of 17 p, resulting in a dividend yield of 3.75%
Dividend Per Share17 p
Dividend Yield3.75%
Payout Ratio62.77%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.16
52-Week Price Change5.36%
50-Day Moving Average1.85K
200-Day Moving Average1.93K
Relative Strength Index (RSI)45.01
Average Volume (3m)7.23M
Important Dates
GlaxoSmithKline upcoming earnings date is Feb 3, 2027, Before Open (Confirmed).
Last Earnings DateOct 28, 2026
Next Earnings DateFeb 3, 2027
Ex-Dividend Date―
Financial Position
GlaxoSmithKline as a current ratio of 0.82, with Debt / Equity ratio of 126.38%
Current Ratio0.82
Quick Ratio0.54
Debt to Market Cap0.23
Net Debt to EBITDA1.23
Interest Coverage Ratio10.23
Taxes
In the past 12 months, GlaxoSmithKline has paid 1.11B in taxes.
Income Tax1.11B
Effective Tax Rate0.15
Enterprise Valuation
GlaxoSmithKline EV to EBITDA ratio is 7.45, with an EV/FCF ratio of 14.86.
EV to Sales2.71
EV to EBITDA7.45
EV to Free Cash Flow14.86
EV to Operating Cash Flow12.12
Balance Sheet
GlaxoSmithKline has £2.96B in cash and marketable securities with £23.70B in debt, giving a net cash position of -£20.74B billion.
Cash & Marketable Securities£2.96B
Total Debt£23.70B
Net Cash-£20.74B
Net Cash Per Share-£5.13
Tangible Book Value Per Share-£1.93
Margins
Gross margin is 73.52%, with operating margin of 21.95%, and net profit margin of 17.50%.
Gross Margin73.52%
Operating Margin21.95%
Pretax Margin22.66%
Net Profit Margin17.50%
EBITDA Margin36.38%
EBIT Margin24.81%
Analyst Forecast
The average price target for GlaxoSmithKline is £2,095.57, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target£2,095.57
Price Target Upside9.97% Upside
Analyst ConsensusHold
Analyst Count14
Revenue Growth Forecast4.28%
EPS Growth Forecast-19.93%